• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症相关血栓形成早期死亡率的预测因素:RIETE数据库分析。

Predictors of Early Mortality in Cancer-Associated Thrombosis: Analysis of the RIETE Database.

作者信息

Tafur Alfonso J, Fuentes Harry, Caprini Joseph A, Rivas Agustina, Uresandi F, Duce Rita, Lopez-Reyes Raquel, Visona Adriana, Merah Adel, Monreal Manuel

机构信息

NorthShore University HealthSystem, Evanston, Illinois, United States.

John Stroger Cook County Hospital, Chicago, Illinois, United States.

出版信息

TH Open. 2018 Apr 19;2(2):e158-e166. doi: 10.1055/s-0038-1642022. eCollection 2018 Apr.

DOI:10.1055/s-0038-1642022
PMID:31249939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6524871/
Abstract

Cancer-associated thrombosis (CT) carries a high, heterogeneous, and poorly predicted likelihood of mortality. Thus, we aimed to define predictors of 30-day mortality in 10,025 patients with CT. In a randomly selected derivation cohort, we used recursive partitioning analysis to detect variables that select for a risk of mortality within 30 days. In a validation cohort, we evaluated our results using Cochran-Armitage test. The most common types of cancer were lung (16%), breast (14%), and colorectal (14%); median age was 69 years (range, 14-101); most had metastatic disease (63%); 13% of patients died within 30 days. In the derivation cohort (  = 6,660), a white blood cell (WBC) count in the highest quartile predicted early mortality (odds ratio, 7.8; 95% confidence interval [CI], 4.6-13.1); and the presence of metastatic disease, pulmonary embolism (PE), and immobility defined the risk of those with normal WBC count. We defined death risk according four sequential questions: (1) Does the patient have an elevated WBC count? (Yes, group D). (2) If no, does the patient have metastasis? (No, group A). (3) If yes, is the patient immobile? (Yes, group D). (4) If no, does the patient have a PE? (Yes, group C; no, group B). In the validation cohort (  = 3,365), the 30-day risk of death was 2.9% in group A (95% CI, 1.9-4.3), compared with 25% in group D (95% CI, 22.5-27.5), and there was a rate escalation between groups ( for trend < 0.01). In conclusion, with four sequential questions, the risk of death in CT can be easily stratified. An elevated WBC count at baseline predicted 30-day mortality better than metastases, PE, or immobility.

摘要

癌症相关血栓形成(CT)具有较高、异质性且难以预测的死亡可能性。因此,我们旨在确定10025例CT患者30天死亡率的预测因素。在一个随机选择的推导队列中,我们使用递归划分分析来检测那些提示30天内死亡风险的变量。在一个验证队列中,我们使用 Cochr an-Armitage检验来评估我们的结果。最常见的癌症类型为肺癌(16%)、乳腺癌(14%)和结直肠癌(14%);中位年龄为69岁(范围14 - 101岁);大多数患者患有转移性疾病(63%);13%的患者在30天内死亡。在推导队列(n = 6660)中,白细胞(WBC)计数处于最高四分位数可预测早期死亡(比值比,7.8;95%置信区间[CI],4.6 - 13.1);而转移性疾病、肺栓塞(PE)和活动受限则决定了白细胞计数正常患者的死亡风险。我们根据四个连续问题来定义死亡风险:(1)患者白细胞计数是否升高?(是,D组)。(2)如果否,患者是否有转移?(否,A组)。(3)如果是,患者是否活动受限?(是,D组)。(4)如果否,患者是否有PE?(是,C组;否,B组)。在验证队列(n = 3365)中,A组30天死亡风险为2.9%(95%CI,1.9 - 4.3),而D组为25%(95%CI,22.5 - 27.5),且各组之间风险呈递增趋势(趋势P < 0.01)。总之,通过四个连续问题,CT患者的死亡风险可轻松分层。基线时白细胞计数升高比转移、PE或活动受限更能预测30天死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/2f3ee93d0cc9/10-1055-s-0038-1642022-i180010-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/811a99a4b0b3/10-1055-s-0038-1642022-i180010-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/9d7d738b9143/10-1055-s-0038-1642022-i180010-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/1fa9e01b09e8/10-1055-s-0038-1642022-i180010-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/2f3ee93d0cc9/10-1055-s-0038-1642022-i180010-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/811a99a4b0b3/10-1055-s-0038-1642022-i180010-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/9d7d738b9143/10-1055-s-0038-1642022-i180010-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/1fa9e01b09e8/10-1055-s-0038-1642022-i180010-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ff/6524871/2f3ee93d0cc9/10-1055-s-0038-1642022-i180010-4.jpg

相似文献

1
Predictors of Early Mortality in Cancer-Associated Thrombosis: Analysis of the RIETE Database.癌症相关血栓形成早期死亡率的预测因素:RIETE数据库分析。
TH Open. 2018 Apr 19;2(2):e158-e166. doi: 10.1055/s-0038-1642022. eCollection 2018 Apr.
2
Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry.癌症合并静脉血栓栓塞患者白细胞计数升高与预后:RIETE注册研究结果
Thromb Haemost. 2008 Nov;100(5):905-11.
3
Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database.RIETE数据库中癌症相关性血栓形成患者早期死亡率的预测
Int Angiol. 2019 Jun;38(3):173-184. doi: 10.23736/S0392-9590.19.04110-5. Epub 2019 May 16.
4
Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry.静脉血栓栓塞和癌症患者的三个月死亡率和临床预测因素。RIETE 登记处的结果。
Thromb Res. 2013 Jan;131(1):24-30. doi: 10.1016/j.thromres.2012.10.007. Epub 2012 Nov 8.
5
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.基于5-氟尿嘧啶治疗转移性结直肠癌患者生存的临床决定因素:3825例患者的多变量分析结果
Ann Oncol. 2002 Feb;13(2):308-17. doi: 10.1093/annonc/mdf034.
6
White blood cell count and mortality in patients with acute pulmonary embolism.白细胞计数与急性肺栓塞患者的死亡率。
Am J Hematol. 2013 Aug;88(8):677-81. doi: 10.1002/ajh.23484. Epub 2013 Jun 20.
7
Which patients with venous thromboembolism are at risk for fatal pulmonary embolism?哪些静脉血栓栓塞患者有发生致命性肺栓塞的风险?
Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):604-5. doi: 10.1038/ncpcardio1308. Epub 2008 Aug 5.
8
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry.预测癌症合并静脉血栓栓塞患者的复发或大出血。RIETE注册研究的结果。
Thromb Haemost. 2008 Sep;100(3):435-9.
9
Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.对无诱因静脉血栓栓塞症(VTE)患者进行癌症检测对癌症及VTE相关死亡率和发病率的影响。
Cochrane Database Syst Rev. 2017 Aug 23;8(8):CD010837. doi: 10.1002/14651858.CD010837.pub3.
10
D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer.伴有和不伴有癌症的急性肺栓塞患者的 D-二聚体水平与 90 天结局。
Thromb Res. 2014 Mar;133(3):384-9. doi: 10.1016/j.thromres.2013.12.044. Epub 2014 Jan 6.

引用本文的文献

1
Incidence and Risk Factors for Venous Thromboembolism in Female Patients Undergoing Breast Surgery.接受乳房手术的女性患者静脉血栓栓塞的发生率及危险因素
Cancers (Basel). 2022 Feb 16;14(4):988. doi: 10.3390/cancers14040988.
2
Happy New Year!新年快乐!
TH Open. 2019 Jan 2;3(1):e1. doi: 10.1055/s-0038-1677005. eCollection 2019 Jan.

本文引用的文献

1
External Validation of Generic and Cancer-Specific Risk Stratification Tools in Patients With Pulmonary Embolism and Active Cancer.在患有肺栓塞和活动性癌症的患者中,通用和癌症特异性风险分层工具的外部验证。
J Natl Compr Canc Netw. 2017 Dec;15(12):1476-1482. doi: 10.6004/jnccn.2017.7004.
2
Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis.临床预测规则在肺栓塞合并癌症患者中的应用:指导门诊管理的荟萃分析。
J Thromb Haemost. 2018 Feb;16(2):279-292. doi: 10.1111/jth.13921. Epub 2018 Jan 15.
3
Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
肺癌患者抗凝治疗与血栓形成及死亡率预防的荟萃分析。
Thromb Res. 2017 Jun;154:28-34. doi: 10.1016/j.thromres.2017.03.024. Epub 2017 Apr 1.
4
Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.癌症相关血栓形成中 Khorana 评分的 RIETE 经验:癌症血栓栓塞性结局的活性癌症血栓形成预测因子。
Thromb Haemost. 2017 Jun 2;117(6):1192-1198. doi: 10.1160/TH16-11-0840. Epub 2017 Mar 9.
5
Symptoms, signs, suspicion and setting: a PESI score for cancer-associated pulmonary embolism?
Eur Respir J. 2017 Jan 4;49(1). doi: 10.1183/13993003.02225-2016. Print 2017 Jan.
6
Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study.疑似和非疑似肺栓塞癌症患者的临床特征和短期转归:EPIPHANY 研究。
Eur Respir J. 2017 Jan 4;49(1). doi: 10.1183/13993003.00282-2016. Print 2017 Jan.
7
Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply.活动性癌症血栓栓塞结局的预测因素:肺癌患者中Khorana评分的验证:回复
J Thromb Haemost. 2017 Mar;15(3):591-592. doi: 10.1111/jth.13592. Epub 2017 Feb 3.
8
Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model.急性肺栓塞:2014 年欧洲心脏病学会风险分层模型预测死亡率。
Eur Respir J. 2016 Sep;48(3):780-6. doi: 10.1183/13993003.00024-2016. Epub 2016 May 12.
9
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.依度沙班用于静脉血栓栓塞症患者的延长抗凝治疗:来自北斋-VTE研究的事后分析
Lancet Haematol. 2016 May;3(5):e228-36. doi: 10.1016/S2352-3026(16)00023-5. Epub 2016 Mar 22.
10
A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.一种经过验证的静脉血栓栓塞风险评分可预测癌症进展和死亡率。
Oncologist. 2016 Jul;21(7):861-7. doi: 10.1634/theoncologist.2015-0361. Epub 2016 Apr 28.